Sponsor Deadline
Posted: 3/30/2022

ASTRO-Myovant Sciences-Pfizer Alliance New Combination Therapy Challenge

PURPOSE: To catalyze new collaborative research opportunities, and to facilitate radiation oncology leadership in scientific discovery with the Myovant Sciences-Pfizer Alliance in the space of multimodality combination therapy. 

Deadline: July 18, 2022

Areas of Interest

Research proposals in the following topic areas are encouraged: • Use of relugolix with definitive radiotherapy (concomitant/adjuvant/neoadjuvant) in prostate cancer patients with High/Very-High Risk, Unfavorable Intermediate Risk, and Regional disease • Use of relugolix with radiotherapy as salvage therapy post treatment with curative intent • Concomitant treatment with other oral oncolytics (e.g., ARIs) • Synchronous oligometastatic/metastatic and oligoprogressive disease 

Eligibility Requirements


To be eligible: • The institution and principal investigator (PI) must be based in the United States. • Only organizations are eligible to receive grants, not individuals nor medical practice groups. • Applicant must be affiliated with a host institution. 

Multiple PIs are allowed and collaborations mentoring young investigators are encouraged. Both early career and experienced investigators are encouraged to apply and consideration will be given to all proposals meeting the selection criteria

Amount Description

• The target budget for each individual project grant is up to US$500,000 (Total costs, which include both direct and indirect costs).  However, individual projects requesting higher amounts will be considered based on scientific merit and funding availability. Overhead (indirect cost) rates of up to 28% of the total proposed project budget are allowed.

• The amount of the Myovant Sciences-Pfizer Alliance funds for any project will depend upon the expert review panel’s (ERP) (also known as the Challenge Judging Panel) evaluation of the proposal and costs involved and will be stated clearly in the approval notification.

Funding for the 2022 ASTRO-Myovant Sciences-Pfizer New Combination Therapy Challenge is up to $2,500,000, across 3-5 projects. 

Funding Type